Woods Cross, Utah Clinical Trials

A listing of Woods Cross, Utah clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients

A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.

resuscitation
hypothermia
cardiac arrest
coma
life support
University of Utah Hospital
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +12 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

University of Utah_Investigational Site Number :8400005
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +22 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome  

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

University of Utah_Investigational Site Number :8400005
 (7.5 away)
  • 0 views
  • 01 Dec, 2025
  • +19 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

schwartz
glioma
neutrophil count
nf2 gene
crizotinib
University of Utah (Site 875)
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
Clinical and Genetic Analysis of ROP

Retinopathy of Prematurity (ROP) is a vascular disease affecting the retinas (back of the eye) of low birth weight infants. Although it can be treated effectively if diagnosed early, it continues to be a leading cause of childhood blindness in the United States and throughout the world. The investigators feel …

pediatric
retinopathy
prematurity
blindness
vascular disease
University of Utah
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +4 other locations
Improving Colonoscopy Quality for Colorectal Cancer Screening in the National VA Healthcare System

High quality screening colonoscopy is critical for colorectal cancer (CRC) prevention in Veterans. There is significant variability in colonoscopy quality in VA that is directly linked to differences in CRC incidence and death. The investigators developed the VA Endoscopy Quality Improvement Program (VA-EQuIP) that the National GI program office will …

screening for colorectal cancer
endoscopy
colorectal cancer
screening colonoscopy
adenoma
VA Salt Lake City Health Care System, Salt Lake City, UT
 (8.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
NCI COVID-19 in Cancer Patients NCCAPS Study

This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects …

hematopoietic and lymphoid cell neoplasm
solid tumor
seizure
hematologic malignancy
rituximab
Farmington Health Center
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +575 other locations